A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2019
At a glance
- Drugs EMD 640744 (Primary) ; Cyclophosphamide; Pembrolizumab
- Indications Ovarian cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors IMV
- 08 Feb 2019 Status changed from planning to recruiting.
- 02 Nov 2018 According to an IMV media release, preliminary data from this trial is expected in 2019.
- 20 Sep 2018 New trial record